Jacques L, et al. - Given that initiating once-daily fluticasone furoate/vilanterol (FF/VI) vs continuing usual care in asthma patients in UK primary care proved efficacious in the Asthma Salford Lung Study, researchers assessed the relative efficacy of initiating FF/VI vs continuing fluticasone propionate/salmeterol (FP/Salm) in a subset of patients with FP/Salm as their baseline intended maintenance therapy enrolled in this secondary analysis. In a random manner, adults with symptomatic asthma were allocated to initiate FF/VI 100[200]/25 µg or continue FP/Salm. For improving asthma control and quality of life, and attenuating asthma exacerbations, a significantly better option was initiating FF/VI rather than continuing with FP/Salm in patients in primary care. Serious adverse events did not differ notably between both treatment approaches.